» Articles » PMID: 27753146

The Pharmacokinetics and Pharmacodynamics of Mycophenolate Mofetil in Younger and Elderly Renal Transplant Recipients

Overview
Specialty Pharmacology
Date 2016 Oct 19
PMID 27753146
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Elderly transplant recipients have a lower incidence of acute rejection, and a higher risk to die from infectious complications. A potential cause may be differences in the pharmacokinetics (PK) or pharmacodynamics (PD) of the immunosuppressive drugs they are taking. This study was designed to comprehensively evaluate the influence of age on the PK and PD of mycophenolic acid (MPA).

Methods: In this study the PK and PD of MPA was studied in 26 elderly and 54 younger renal transplant recipients treated with mycophenolate mofetil and tacrolimus. Patients were sampled repetitively, both before and during the first 6 months after kidney transplantation. Age-related variability in MPA PK, baseline IMPDH activity, as well as MPA-induced IMPDH inhibition were studied.

Results: The IMPDH activity pre-transplantation did not differ between elderly and younger patients. Neither IMPDH activity pre-transplantation nor maximum IMPDH inhibition was significantly correlated with the patients' age. The area under the MPA plasma concentration-time curve (AUC ) and the area under the effect (IMPDH activity)-time curve (AEC ) from 0 to 12 h were also not significantly different between the two groups. We found no significant differences in EC and E between elderly and younger patients.

Conclusions: Age did not significantly affect the PK or PD of MPA. It is unlikely that the lower incidence of acute rejection in elderly patients, or the higher risk to die from a severe infection in elderly patients is due to different handling of MPA in the elderly.

Citing Articles

Trends in Precision Medicine and Pharmacogenetics as an Adjuvant in Establishing a Correct Immunosuppressive Therapy for Kidney Transplant: An Up-to-Date Historical Overview.

Belardi R, Pacifici F, Baldetti M, Velocci S, Minieri M, Pieri M Int J Mol Sci. 2025; 26(5).

PMID: 40076585 PMC: 11900248. DOI: 10.3390/ijms26051960.


Revolutionizing Blood Collection: Innovations, Applications, and the Potential of Microsampling Technologies for Monitoring Metabolites and Lipids.

Bossi E, Limo E, Pagani L, Monza N, Serrao S, Denti V Metabolites. 2024; 14(1).

PMID: 38248849 PMC: 10818866. DOI: 10.3390/metabo14010046.


Age associations with tacrolimus and mycophenolic acid pharmacokinetics in stable Black and White kidney transplant recipients: Implications for health inequities.

Tornatore K, Attwood K, Venuto R, Murray B Clin Transl Sci. 2023; 16(5):861-871.

PMID: 36840340 PMC: 10175981. DOI: 10.1111/cts.13495.


Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum.

Nakafero G, Grainge M, Card T, Mallen C, Riley R, Van der Windt D Rheumatol Adv Pract. 2022; 6(2):rkac046.

PMID: 35702565 PMC: 9187914. DOI: 10.1093/rap/rkac046.


Pharmacokinetics and pharmacodynamics profiles of enteric-coated mycophenolate sodium in female patients with difficult-to-treat lupus nephritis.

Chariyavilaskul P, Phaisal W, Kittanamongkolchai W, Rukrung C, Anutrakulchai S, Avihingsanon Y Clin Transl Sci. 2022; 15(7):1776-1786.

PMID: 35570339 PMC: 9283741. DOI: 10.1111/cts.13295.


References
1.
Miura M, Satoh S, Kagaya H, Saito M, Inoue T, Tsuchiya N . No impact of age on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone 1 month after renal transplantation. Eur J Clin Pharmacol. 2009; 65(10):1047-53. DOI: 10.1007/s00228-009-0721-9. View

2.
van Gelder T, Le Meur Y, Shaw L, Oellerich M, DeNofrio D, Holt C . Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006; 28(2):145-54. DOI: 10.1097/01.ftd.0000199358.80013.bd. View

3.
Raggi M, Siebert S, Steimer W, Schuster T, Stangl M, Abendroth D . Customized mycophenolate dosing based on measuring inosine-monophosphate dehydrogenase activity significantly improves patients' outcomes after renal transplantation. Transplantation. 2010; 90(12):1536-41. DOI: 10.1097/TP.0b013e3182000027. View

4.
Wang C, Meng F, Chen L, Ren B, Li S, Fei J . Population pharmacokinetics of mycophenolic acid in senile Chinese kidney transplant recipients. Transplant Proc. 2007; 39(5):1392-5. DOI: 10.1016/j.transproceed.2007.02.082. View

5.
Smits T, Cox S, Fukuda T, Sherbotie J, Ward R, Goebel J . Effects of unbound mycophenolic acid on inosine monophosphate dehydrogenase inhibition in pediatric kidney transplant patients. Ther Drug Monit. 2014; 36(6):716-23. PMC: 4687018. DOI: 10.1097/FTD.0000000000000081. View